Treatment for the underlying disorder that caused the DIC should be considered first. Various options exist, given the diversity of the disorders responsible.
The treatment for DIC itself is above all symptomatic and aimed at restoring haemostatic balance.
For serious haemorrhagic manifestations, the aim of treatment is to limit bleeding using platelet concentrates and fresh frozen plasma.
There are no specific treatments for the thrombotic manifestations of DIC. The use of heparins, fibrinolytics or antithrombin is not recommended. Activated protein C (drotrecogin) was recently withdrawn from the market due to lack of efficacy.
In the world
Stago Group Companies